methadone has been researched along with Opiate Overdose in 21 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
Opiate Overdose: Accidental or deliberate use of an OPIOID in excess of normal dosage. It includes overdose for prescription and illicit opioids.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether the methadone take-home policy change was associated with drug overdose deaths among different racial, ethnic, and sex groups." | 4.31 | Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses. ( Bao, Y; Harris, RA; Long, JA; Mandell, DS, 2023) |
| "The rapid increase in opioid overdose and opioid use disorder (OUD) over the past 20 years is a complex problem associated with significant economic costs for healthcare systems and society." | 2.72 | Economic Evaluation in Opioid Modeling: Systematic Review. ( Beaulieu, E; Cerdá, M; Connolly, A; DiGennaro, C; Hamilton, A; Hyder, A; Jalali, MS; Keyes, KM; Stringfellow, E, 2021) |
| " The restrictions on methadone availability including take-home dosing were loosened during the COVID-19 pandemic although there have been concerns about the high street value of diverted methadone." | 1.91 | Examination of methadone involved overdoses during the COVID-19 pandemic. ( Kaufman, DE; Kennalley, AL; McCall, KL; Piper, BJ, 2023) |
| "Buprenorphine was associated with greater protection against overdose death than methadone for clients with circulatory (MSM aIRR = 0." | 1.91 | Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17. ( Ali, R; Degenhardt, L; Hickman, M; Jones, NR; Larney, S; Nielsen, S, 2023) |
| "Buprenorphine availability has increased and relaxed regulations reduces barriers in general medical settings common in rural areas." | 1.91 | Augmenting project ECHO for opioid use disorder with data-informed quality improvement. ( Cox, KM; Doyle, M; Marsch, LA; McLeman, BM; Murray, OB; Ryer, J; Saunders, EC; Watts, D, 2023) |
| "Medications for opioid use disorder (MOUD) reduce opioid overdose (OD) deaths; however, prevalence and misuse of MOUD in ED patients presenting with opioid overdose are unclear, as are any impacts of existing MOUD prescriptions on subsequent OD severity." | 1.72 | Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity. ( Allen, LR; Manini, AF; Nobel, I; Richardson, LD; Shastry, S; Vidal, K, 2022) |
| "Relaxed restrictions on medications for opioid use disorder created opportunities for improved patient-centered care." | 1.72 | "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. ( Bagley, SM; Gunn, CM; Harris, MTH; Lambert, AM; Maschke, AD; Walley, AY, 2022) |
| "Primary outcomes were opioid overdose, interruption in OAT, and OAT discontinuation." | 1.72 | Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. ( Antoniou, T; Bozinoff, N; Campbell, TJ; Garg, R; Gomes, T; Kitchen, SA; Men, S; Munro, C; Tadrous, M; Werb, D; Wyman, J, 2022) |
| "The primary outcome was opioid overdose (fatal and non-fatal) while on treatment, with secondary outcomes including opioid overdose (first 30 days of treatment), treatment discontinuation, health-care interactions related to treatment of opioid use disorder, receiving a weekly supply of take-home doses and opioid overdose within 30 days of treatment discontinuation." | 1.72 | Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. ( Antoniou, T; Bozinoff, N; Campbell, T; Gomes, T; Mamdani, M; McCormack, D; Munro, C; Paterson, JM; Sproule, B; Tadrous, M, 2022) |
| "If methadone distribution was to expand to FQHCs, more counties and a larger area of Georgia would have greater access to methadone treatment." | 1.72 | Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis. ( Anwar, T; Duever, M; Jayawardhana, J, 2022) |
| "Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)." | 1.72 | Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. ( Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022) |
| "The proportion of opioid overdose deaths increased by 36% post-COVID emergence (95% CI: 14%, 59%)." | 1.72 | Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas. ( Fairman, BJ; Rezaeiahari, M, 2022) |
| "Methadone maintenance treatment (MMT) is reco-gnized as a reference treatment for opioid dependence." | 1.62 | Methadone overdose in patients following methadone mainte- nance treatment:A three years overview in the district of Bari (South-Italy). ( De Donno, A; Favia, M; Introna, F; Mita, Q; Santoiemma, I; Strisciullo, G, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 21 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shastry, S | 1 |
| Nobel, I | 1 |
| Allen, LR | 1 |
| Richardson, LD | 1 |
| Vidal, K | 1 |
| Manini, AF | 1 |
| Harris, MTH | 1 |
| Lambert, AM | 1 |
| Maschke, AD | 1 |
| Bagley, SM | 1 |
| Walley, AY | 1 |
| Gunn, CM | 1 |
| Gomes, T | 2 |
| Campbell, TJ | 1 |
| Kitchen, SA | 1 |
| Garg, R | 1 |
| Bozinoff, N | 2 |
| Men, S | 1 |
| Tadrous, M | 2 |
| Munro, C | 2 |
| Antoniou, T | 2 |
| Werb, D | 1 |
| Wyman, J | 1 |
| McCormack, D | 1 |
| Campbell, T | 1 |
| Paterson, JM | 1 |
| Mamdani, M | 1 |
| Sproule, B | 1 |
| Tabatabaeepour, N | 1 |
| Morgan, JR | 1 |
| Jalali, A | 1 |
| Kapadia, SN | 1 |
| Meinhofer, A | 1 |
| Denham, A | 1 |
| Vasu, T | 1 |
| Avendano, P | 1 |
| Boslett, A | 1 |
| Mendoza, M | 1 |
| Hill, EL | 1 |
| Jones, CM | 1 |
| Compton, WM | 1 |
| Han, B | 1 |
| Baldwin, G | 1 |
| Volkow, ND | 1 |
| Anwar, T | 1 |
| Duever, M | 1 |
| Jayawardhana, J | 1 |
| Calcaterra, SL | 1 |
| Bottner, R | 1 |
| Martin, M | 1 |
| Englander, H | 1 |
| Weinstein, ZM | 1 |
| Weimer, MB | 1 |
| Lambert, E | 1 |
| Ronan, MV | 1 |
| Huerta, S | 1 |
| Zaman, T | 1 |
| Ullal, M | 1 |
| Peterkin, AF | 1 |
| Torres-Lockhart, K | 1 |
| Buresh, M | 1 |
| O'Brien, MT | 1 |
| Snyder, H | 1 |
| Herzig, SJ | 1 |
| Miano, TA | 1 |
| Wang, L | 1 |
| Leonard, CE | 1 |
| Brensinger, CM | 1 |
| Acton, EK | 1 |
| Dawwas, GK | 1 |
| Bilker, WB | 1 |
| Soprano, SE | 1 |
| Nguyen, TPP | 1 |
| Woody, G | 1 |
| Yu, E | 1 |
| Neuman, M | 1 |
| Li, L | 1 |
| Hennessy, S | 1 |
| Rezaeiahari, M | 1 |
| Fairman, BJ | 1 |
| Kleinman, RA | 2 |
| Sanches, M | 2 |
| Kaufman, DE | 1 |
| Kennalley, AL | 1 |
| McCall, KL | 1 |
| Piper, BJ | 1 |
| Larney, S | 1 |
| Jones, NR | 1 |
| Hickman, M | 1 |
| Nielsen, S | 1 |
| Ali, R | 1 |
| Degenhardt, L | 1 |
| Murray, OB | 1 |
| Doyle, M | 1 |
| McLeman, BM | 1 |
| Marsch, LA | 1 |
| Saunders, EC | 1 |
| Cox, KM | 1 |
| Watts, D | 1 |
| Ryer, J | 1 |
| Harris, RA | 1 |
| Long, JA | 1 |
| Bao, Y | 1 |
| Mandell, DS | 1 |
| Russoniello, K | 1 |
| Harrington, C | 1 |
| Beydoun, S | 1 |
| Borrego, L | 1 |
| Beaulieu, E | 1 |
| DiGennaro, C | 1 |
| Stringfellow, E | 1 |
| Connolly, A | 1 |
| Hamilton, A | 1 |
| Hyder, A | 1 |
| Cerdá, M | 1 |
| Keyes, KM | 1 |
| Jalali, MS | 1 |
| Fairley, M | 1 |
| Humphreys, K | 1 |
| Joyce, VR | 1 |
| Bounthavong, M | 1 |
| Trafton, J | 1 |
| Combs, A | 1 |
| Oliva, EM | 1 |
| Goldhaber-Fiebert, JD | 1 |
| Asch, SM | 1 |
| Brandeau, ML | 1 |
| Owens, DK | 1 |
| Favia, M | 1 |
| Santoiemma, I | 1 |
| Mita, Q | 1 |
| Strisciullo, G | 1 |
| Introna, F | 1 |
| De Donno, A | 1 |
| Hallowell, BD | 1 |
| Weidele, HR | 1 |
| Daly, M | 1 |
| Chambers, LC | 1 |
| Scagos, RP | 1 |
| Gargano, L | 1 |
| McDonald, J | 1 |
2 reviews available for methadone and Opiate Overdose
| Article | Year |
|---|---|
Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Hospitalization; Humans; Methadone; Opiate Overdose; Opioi | 2022 |
Economic Evaluation in Opioid Modeling: Systematic Review.
Topics: Analgesics, Opioid; Costs and Cost Analysis; Humans; Methadone; Models, Economic; Naloxone; Narcotic | 2021 |
19 other studies available for methadone and Opiate Overdose
| Article | Year |
|---|---|
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospital Mortality; Humans; Length of Stay; Logist | 2022 |
"No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
Topics: Adolescent; Adult; Aged; Boston; COVID-19; Female; Humans; Male; Methadone; Middle Aged; Opiate Over | 2022 |
Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Topics: Adult; Analgesics, Opioid; Buprenorphine; COVID-19; Female; Humans; Male; Medication Adherence; Meth | 2022 |
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Drug Ov | 2022 |
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Overdose; Opiate Substitution T | 2022 |
Coroner county systems are associated with a higher likelihood of unclassified drug overdoses compared to medical examiner county systems.
Topics: Analgesics, Opioid; Coroners and Medical Examiners; Drug Overdose; Heroin; Humans; Methadone; Opiate | 2022 |
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.
Topics: Analgesics, Opioid; Drug Overdose; Humans; Methadone; Opiate Overdose; Opiate Substitution Treatment | 2022 |
Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis.
Topics: Analgesics, Opioid; Drug Overdose; Georgia; Humans; Methadone; Opiate Overdose; Opiate Substitution | 2022 |
Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Topics: Baclofen; Bayes Theorem; Benzodiazepines; Buprenorphine; Clonidine; Drug Interactions; Fluconazole; | 2022 |
Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas.
Topics: Analgesics, Opioid; Arkansas; COVID-19; Drug Overdose; Fentanyl; Humans; Methadone; Methamphetamine; | 2022 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Examination of methadone involved overdoses during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Drug Overdose; Humans; Methadone; Opiate Overdose; Opioid-Related Diso | 2023 |
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Topics: Aged; Analgesics, Opioid; Australia; Buprenorphine; Cohort Studies; Drug Overdose; Humans; Methadone | 2023 |
Augmenting project ECHO for opioid use disorder with data-informed quality improvement.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid | 2023 |
Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; COVID-19; Drug Overdose; Female; Humans; Ma | 2023 |
State-Specific Barriers to Methadone for Opioid Use Disorder Treatment.
Topics: Humans; Methadone; Opiate Overdose; Opioid-Related Disorders | 2023 |
Cost-effectiveness of Treatments for Opioid Use Disorder.
Topics: Adult; Buprenorphine; Combined Modality Therapy; Cost-Benefit Analysis; Delayed-Action Preparations; | 2021 |
Methadone overdose in patients following methadone mainte- nance treatment:A three years overview in the district of Bari (South-Italy).
Topics: Humans; Italy; Methadone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Overdose; Opiate Substitution Treatment | 2021 |